Health experts and the International PCOS Network have renamed Polycystic Ovary Syndrome to Polyendocrine Metabolic Ovarian Syndrome (PMOS).
The change aims to shift the medical focus away from the ovaries alone. By acknowledging the condition's impact on multiple endocrine systems, experts believe the new terminology will improve patient care and understanding.
The name change was instituted on May 12, 2026 [1]. This transition follows growing recognition that the condition is a complex metabolic issue rather than a localized ovarian problem. The new name, PMOS, explicitly incorporates the endocrine and metabolic components of the disorder.
Experts in Jersey and the International PCOS Network said the updated name is more representative of the condition. They noted that the previous terminology often led to a narrow clinical focus on the ovaries, which could overlook the systemic nature of the illness.
The condition is widespread, affecting roughly one in eight women worldwide [2]. Because it involves various hormone-producing glands and metabolic processes, the systemic approach is intended to lead to more comprehensive diagnostic and treatment strategies.
Medical professionals said the shift is intended to reduce misconceptions about the disease. By highlighting the polyendocrine aspect, the name acknowledges that the condition involves several glands and hormones, not just those in the reproductive system.
This global announcement emphasizes a move toward precision medicine. By accurately naming the metabolic and endocrine drivers of the syndrome, clinicians may better identify risk factors and tailor interventions to the individual needs of the patient.
“The condition formerly known as Polycystic Ovary Syndrome (PCOS) has been renamed Polyendocrine Metabolic Ovarian Syndrome (PMOS)”
The transition from PCOS to PMOS represents a fundamental shift in clinical perspective, moving from an organ-specific diagnosis to a systemic metabolic one. By redefining the condition as a polyendocrine disorder, the medical community is prioritizing the hormonal and metabolic drivers of the disease over the physical presence of ovarian cysts, which may not be present in all patients. This change is likely to influence how the condition is screened for and treated on a global scale.
